Philip R.
- Country
- Belgium
- Department
- NA
Research Overview
- Efficacy and Safety of Sarilumab Dose Levels with a 52‑Week Prednisone Taper in Adults with Early Polymyalgia Rheumatica: Randomized Double‑Blind Placebo‑Controlled Trial
- Rituximab Tapering Strategies in Rheumatoid Arthritis: Interval Prolongation Versus Disease Activity-Guided Dose Reduction
- Evaluation of Methotrexate and Glucocorticoid Regimen with Optional Etanercept in Early Rheumatoid Arthritis: A Randomized, Multicenter Trial
Data & Insights
Has run more than one trial at 13 of 67 partner sites.
Specializations
Rheumatoid Arthritis Management
This investigator specializes in studying innovative treatment approaches for rheumatoid arthritis, with particular emphasis on early intervention strategies and remission induction protocols.
- Early RA Treatment Optimization
- Remission Induction Therapies
- Long-term Disease Management
The research focus includes evaluating treatment adaptations and monitoring disease progression in early-stage arthritis patients.
Biological Therapy Research
The investigator conducts research on biological therapeutics, particularly examining the effectiveness of TNF blockade and rituximab in rheumatoid arthritis treatment.
- Biological Agent Administration
- Treatment Tapering Strategies
- Therapy Optimization Protocols
Their work includes investigating optimal timing and dosing strategies for biological therapies.
Clinical Outcomes Assessment
The investigator focuses on evaluating long-term effectiveness of various treatment strategies through comprehensive disease activity monitoring and outcome measurements.
- Disease Activity Monitoring
- Treatment Response Assessment
- Safety Profile Evaluation
Research includes analyzing disease burden evolution and treatment response patterns over extended periods.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.